Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age70+
SponsorLarysa Sanchez

About this trial

Induction therapy approaches in recent years have evolved, now utilizing triple or quadruple drug regimens in the majority of patients. By combining anti-CD38 antibodies, proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and steroids, patients achieve longer remissions with their first- and second-line therapies but also become refractory to most or all three major drug classes earlier. For patients who are refractory to at least 3 of the commonly administered PIs and IMiDs, occurring after 2 lines of therapy in many, the median overall survival is only 5 months. Elderly, frail patients are not often candidates at this point for aggressive therapies like stem cell transplantation and CAR T-cell therapy thus necessitating effective yet tolerable treatments for elderly patients in early relapse (1-3 prior therapy). Talquetamab is a GPRC5DxCD3 bispecific antibody that redirects patients' T cells to myeloma cells which express GPRC5D. In the phase 1 MonumenTAL-1, heavily pretreated patients with a median of 6 prior lines of therapy attained a 70% response rate with 405 μg/kg of subcutaneous (SC) talquetamab. Importantly, subcutaneous talquetamab was found to be tolerable for the treated population, which included 28% of patients aged ≥70, with only three patients experiencing dose-limiting toxicities in the form of grade 3 rashes which responded to steroids. The anti-CD38 antibody daratumumab eliminates CD38-positive T and B regulatory cells, potentiates the activity of bispecific antibodies like talquetamab, and may improve its efficacy when used in combination. The aim of this study will be to assess the efficacy and safety of treating elderly patients with relapsed/refractory multiple myeloma with at least ≥2 prior lines of therapy with subcutaneous talquetamab. Patients who have progressive disease on talquetamab or who fail to respond after 3 cycles will have subcutaneous daratumumab added to their regimen.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Multiple myeloma diagnosis according to the IMWG diagnostic criteria

Serum M-protein level ≥0.5 g/dL (central laboratory)

Urine M-protein level ≥200 mg/24 hours (central laboratory)

Light chain multiple myeloma without measurable M-protein in the serum or the urine: serum immunoglobulin free light chain ≥10 mg/dL or >100 mg/L (central laboratory) provided the serum free light chain ratio is abnormal (0.22 to 1.52 [central laboratory])

Disqualifiers

Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients (refer to the talquetamab and daratumumab Investigator's Brochure and appropriate prescribing information).

Prior treatment with T-cell-engaging antibodies

Gene-modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells) within 3 months

Targeted therapy, epigenetic therapy, or treatment with an investigational drug or an invasive investigational medical device within 21 days or at least 5 half-lives, whichever is less.

Trial design

Design model

Sequential

Treatments tested in this trial

  • Talquetamab

    Drug

    SC monotherapy starting with three step-up doses followed by the standard 800 μg/kg dose every other week. Cycles will be 28 days long.

  • Daratumumab

    Drug

    SC at the standard dose (weekly for 2 cycles, every other week for 4 cycles, monthly thereafter)

Treatment groups

23 Participants
are divided into 2 treatment groups
Group A: Talquetamab SC monotherapyExperimental treatment 1 intervention
Group B: Talqeutemab SC + Daratumumab SCExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Objective Response Rate (ORR)

ORR defined as the proportion of patients who achieve ≥PR according to IMWG criteria in the intention-to-treat population in Part 1

Time frame
Completion of part 1 of the study after completion of 3 cycles (each cycle is 28 days each) or until PD, whichever occurs first.

Secondary outcomes

1

Time to progression (TTP) for talquetamab monotherapy

Time to progression (TTP) defined as the duration from the first date of study treatment to the date of first documented evidence of PD or death in Part 1, whichever comes first

Time frame
Evaluated continuously until end of study (due to disease progression or death from any cause, whichever comes first), assessed up to 36 months
2

Progression-free survival (PFS) for talquetamab monotherapy

PFS defined as the duration from the first date of study treatment to the date of first documented evidence of PD or death in Part 1, whichever comes first

Time frame
Evaluated continuously until end of study (due to disease progression or death from any cause, whichever comes first), assessed up to 36 months
3

Overall survival (OS) for talquetamab monotherapy

OS defined as the duration from the first date of study treatment to the date of the subject's death

Time frame
Evaluated continuously until end of study (due to disease progression or death from any cause, whichever comes first), assessed up to 36 months
4

Duration of response (DOR) for talquetamab monotherapy

DOR defined as the duration from the date of initial attainment of ≥PR to first documented evidence of progressive disease (PD) in Part 1

Time frame
Evaluated continuously until end of study (due to disease progression or death from any cause, whichever comes first), assessed up to 36 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Larysa Sanchez

Lead sponsor

Icahn School of Medicine at Mount Sinai

Sponsor institution

Janssen Research & Development, LLC

Collaborator